Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAPTOP pancreatic cancer phase 1/2 study
2024-518173-34-00Phase 2Completed
- Sponsor
- Capital Region of Denmark
- Start
- Oct 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab, ipilimumab, nab-paclitaxel and gemcitabine in pancreatic cancer (PC), sponsored by Capital Region of Denmark. Primary endpoint: Safety. Started Oct 2024; status: completed.
02
Drugs
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2024-518173-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518173-34-00.